Skip to main content

Dermatology

An emulation trial shows that Humira biosimilars (Amjevita & Imraldi) were equivalent to Humira in psoriasis & achieving PASI <=2, both for new biologic starts and for biologic switchers. https://t.co/8lTGGs2rbP https://t.co/T6rTJ5ESj2
Dr. John Cush @RheumNow( View Tweet )
Bullhead Sign in #SAPHO Syndrome ▶️Synovitis, ▶️Acne ▶️Pustulosis ▶️Hyperostosis ▶️Osteitis 👉🏽https://t.co/ownI4Q543w via @MayoProceedings https://t.co/FXlTtmsDDX
Dr Ai Lyn Tan @DrAiLynTan( View Tweet )
✅ Management of #REFRACTORY skin manifestations in patients with #LUPUS ➡️ my practical tips 💪 for #PANLAR2025 🇲🇽 https://t.co/KnJO0eXI4W
Laurent ARNAUD @Lupusreference( View Tweet )
JAMA Pt Education handout - Scleroderma https://t.co/UpK24WfyNF

Dr. John Cush @RheumNow( View Tweet )

Osteoarthritis Risky Business (4.18.2025)

Dr. Jack Cush reviews the news and Journal reports from this week on RheumNow.com.  Osteoarthritis patients have unique risks and synovial fluid WBC numbers can tell you when to worry about septic arthritis in gout and pseudogout patients.

Read Article

The Increasing Cost of First-Line Biologics for Plaque Psoriasis

A national commercial claims analysis of first-line use of biologics in biologic−naive plaque psoriasis patients found a near doubling of net treatment costs from 2007 to 2021 ($21 236 to $47 125). Despite the increasing costs, the 2021 average cost could have been 44% lower if the lowest-

Read Article
JAMA Pt Education handout - Scleroderma https://t.co/UpK24WfyNF

Dr. John Cush @RheumNow( View Tweet )

Anti-muscarinic 3 Abs are assoc w/ severe GI Dz in systemic Sclerosis. 132 SSc pts (enrich for GI Sxs) - 39% had anti-M3R Abs; 25% high-titer M3R+. Hi titer M3R+ pts had more diffuse Dz (44% vs 23%), GI severity (91% vs 70%), RNPC3+ (18% vs 6%), U1RNP+(21 vs 2%) https://t.co/j8ZWFY4fgx
Dr. John Cush @RheumNow( View Tweet )
Sjogrens is a hot area in drug development: “Sjogren’s Syndrome Pipeline Insight 2025” report provides comprehensive insights about 20+ companies and 22+ pipeline drugs, including: nipocalimab VAY736 (ianalumab) HZN-1116 AMG 329 R-2487 https://t.co/sVbyPLi2Um https://t.co/IlvthM7qyG
Dr. John Cush @RheumNow( View Tweet )
Patient info on Sweets Syndrome: acute febrile neutrophilic dermatosis https://t.co/0q93q2NVc9 https://t.co/cE3LA8LaRQ
Dr. John Cush @RheumNow( View Tweet )

EMR Messaging Woes (4.11.2025)

Dr. Jack Cush reviews the news, journal reports and regulatory approvals from this past week on RheumNow.com

Read Article
Metanalysis showed no increased risk of serious infx (SIE) w/ JAK inhibitors use in pts w/ immune-mediated inflammatory skin diseases -- 32 RCTs, 11,917 pts found SIE in 0.62% on JAKi vs 0.51% controls. Meta-analysis found no significant increase in risk of serious infection https://t.co/ugH72nk8bZ
Dr. John Cush @RheumNow( View Tweet )

An Epidural Letdown (4.4.2025)

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.

Read Article
EMA approved a record 28 biosimilars in 2024 for cancer, osteoporosis, macular degeneration, and immune-related diseases like plaque psoriasis, ulcerative colitis, and Crohn’s disease https://t.co/NNzKRalLvF https://t.co/nfX082a7ON
Dr. John Cush @RheumNow( View Tweet )

Cancer Survival with TNF Inhibitors (3.28.2025)

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com

Read Article

Treating chronic inflammatory diseases with JAK inhibitors

Science Daily

Janus kinase inhibitors (JAKis) are an important treatment option for people with chronic inflammatory diseases such as rheumatoid arthritis, psoriasis, Crohn's disease or ulcerative colitis. Since their approval, the indications for these medical

Read Article

Axial Involvement in Psoriatic Arthritis

Analysis of a Greek Psoriatic Arthritis (PsA) cohort shows that nearly one quarter of patients have axial involvement, and among them, ∼30% have isolated spinal axPsA and nr-axSpA, respectively.

Read Article
Congratulations to Dr. Joseph Merola (Rheumatologists & Chair of Dermatology at UT Southwestern) on his appointment to the Board of Directors for the American Academy of Dermatology (AAD) https://t.co/TxjuZWeXoJ https://t.co/Mo7PwLWD5f
Dr. John Cush @RheumNow( View Tweet )

2024 Rheumatology Year in Review

2024 was a year of surprising new growth in technology, with the expansion of new therapeutic options for many patients and clinicians.  While these many advances offer new hope, they are countered by disappointments and gapping unmet needs in rheumatology. Below is my top 10 list

Read Article

Hydroxychloro-King (3.7.2025)

Dr. Jack Cush reviews the news, journal reports and regulatory actions from the past week on RheumNow.com

Read Article

Early Hydroxychloroquine Slows Cutaneous Lupus Progression

A prospective study of patients with limited cutaneous lupus erythematosus shows that early introduction of hydroxychloroquine may prevent progression to systemic lupus erythematosus.

Read Article
Misdiagnosis of Dermatomyositis JAMA Dermatology reports a retrospective cohort study from Johns Hopkins reviewing mimic of dermatomyositis (DM), suggesting that DM and especially clinically amyopathic DM (CADM) are commonly and initially misdiagnosed as inflammatory skin… https://t.co/2SbGxxcPLm https://t.co/TtoxFIXg3Q
Dr. John Cush @RheumNow( View Tweet )

Opioid Deaths are Down (2.28.2025)

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.  Opioid deaths are down, IL-33 levels are up and Weight loss is in the news again this week!

Read Article

Diagnoses via Immune ‘Fingerprints’

Science and researchers at Stanford Medicine have reported the use of Mal-ID (machine learning for immunological diagnosis) to analyze B and T cell receptors sequences from human blood, showing the ability to predict health status (healthy vs diseased) and discriminate between distinct

Read Article

CRP and Hidradenitis Supprativa

A post hoc analysis of 2 phase 3 randomized clinical trials (PIONEER I and II)  of adalimumab vs Placebo in patients with active Hidradenitis suppurativa (HS) demonstrated more severe HS that was associated with elevated CRP had a higher BMI. Adalimumab was equally effective in patients

Read Article
×